Related scientific articles (all)

Treatment of febrile neutropenia is expensive: prevention is the answer.

Authors : Klastersky J, Paesmans M
Year : 2011
Journal : Onkologie
Volume : 34(5)
Pages : 226-8

Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?

Authors : Bozovic-Spasojevic I, Azim HA, Paesmans M, Suter T, Piccart-Gebhart M, de Azambuja E
Year : 2011
Journal : Lancet Oncol
Volume : 12(3)
Pages : 209-11

Invasive mechanical ventilation in cancer patients. Prior non invasive ventilation is a poor prognostic factor.

Authors : Meert AP, Berghmans T, Markiewicz E, Hardy M, Nayer N, Paesmans M, Sculier JP
Year : 2011
Journal : J BUON
Volume : 16(1)
Pages : 160-5

C-erbB-3 expression in non-small cell lung cancer (NSCLC) patients treated by Erlotinib.

Authors : CsToth I, Anthoine G, Berghmans T, Mascaux C, Paesmans M, Sculier JP, Meert AP
Year : 2011
Journal : Anticancer Res
Volume : 31(1)
Pages : 281-5

Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables.

Authors : Berghmans T, Paesmans M, Sculier JP
Year : 2011
Journal : Ther Adv Med Oncol
Volume : 3(3)
Pages : 127-38

Positron emission tomography with 18F-FDG and cancer response to chemotherapy].

Authors : van Ruychevelt V, Garcia C, Meert AP, Berghmans T, Paesmans M, Flamen P, Sculier JP
Year : 2011
Journal : Rev Mal Respir
Volume : 28(5)
Pages : 618-25

Validation and comparison of several published prognostic systems for patients with small cell lung cancer.

Authors : Paesmans M, Lafitte JJ, Lecomte J, Berghmans T, Efremidis A, Giner V, Van Cutsem O, Scherpereel A, Meert AP, Leclercq N, Van Houtte P, Sculier JP
Year : 2011
Journal : Eur. Respir. J.
Volume : 38(3)
Pages : 657-63

Febrile neutropenia: a critical review of the initial management.

Authors : Klastersky J, Awada A, Paesmans M, Aoun M
Year : 2011
Journal : Crit Rev Oncol Hematol
Volume : 78(3)
Pages : 185-94